Loading...
Please wait, while we are loading the content...
Similar Documents
Should minimal residual disease negativity be the end point of myeloma therapy?
| Content Provider | Scilit |
|---|---|
| Author | Anderson, Kenneth C. |
| Copyright Year | 2017 |
| Description | Publisher9s Note: This article has a companion Counterpoint by Sonneveld. Publisher9s Note: Join in the discussion of these articles at Blood Advances Community Conversations. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728451/pdf |
| Ending Page | 521 |
| Page Count | 5 |
| Starting Page | 517 |
| DOI | 10.1182/bloodadvances.2016000117 |
| Journal | Blood advances |
| Issue Number | 8 |
| Volume Number | 1 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2017-03-14 |
| Access Restriction | Open |
| Subject Keyword | Hematology Join Publisher's Note Residual Disease Minimal Residual Myeloma Therapy Sonneveld Disease Negativity Advances Community Blood Advances Journal: Blood advances (Vol- 101, Issue- 8) |
| Content Type | Text |
| Resource Type | Article |